Full-Time
Senior Engineer
IT, GxP Infrastructure & Systems
Updated on 9/10/2026
Rocket Pharmaceuticals
201-500 employees
Develops gene therapies with AAV platform
Compensation Overview
$100k - $133k/yr
Cranbury, NJ, USA
Remote
Bachelor's
 IT Operations (1) |
|---|
Get referred to Rocket Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree in IT, Computer Science, Engineering, or a related discipline is preferred; equivalent education and experience will be considered.
- Four to six years of experience administering and supporting enterprise infrastructure, preferably within a pharmaceutical, biotechnology, medical device, or other GxP-regulated environment.
- Experience supporting Microsoft Windows Server, VMware vSphere, including vCenter and ESXi, Microsoft Azure, Microsoft 365, Microsoft Entra ID, Active Directory, Group Policy, DNS, DHCP, and enterprise identity management platforms including Okta.
- Experience administering enterprise servers, storage, backup, and endpoint management solutions, including Lenovo ThinkSystem servers, Lenovo/NetApp storage, Druva, NinjaOne, Microsoft Intune, or comparable technologies.
- Experience supporting enterprise networking and security technologies, including Cisco Nexus, Cisco Meraki, Fortinet FortiGate firewalls, VPNs, TCP/IP, routing, switching, wireless networking, and CrowdStrike Falcon endpoint security.
- Experience deploying operating systems, infrastructure, and GxP system patches; performing preventative maintenance, infrastructure lifecycle management, disaster recovery testing, and technology refresh activities.
- Experience using ServiceNow or a similar IT Service Management platform, with knowledge of infrastructure change management and operational support processes.
- Working knowledge of PowerShell or other scripting languages, infrastructure automation, cGMP, GxP, Computer System Validation, data integrity principles, and 21 CFR Part 11 requirements.
- Experience supporting validated infrastructure within a pharmaceutical, biotechnology, medical device, or other regulated environment, with a strong understanding of GxP compliance, Computer System Validation, data integrity, and audit readiness.
- Ability to work outside standard business hours occasionally to support GxP activities, system implementations, upgrades, maintenance, audits, inspections, and critical issue resolution.
- Ability to lift, carry, push, and/or pull equipment and materials weighing up to 25 pounds occasionally.
- Ability to wear required personal protective equipment and comply with safety, security, and GxP requirements while working in regulated environments.
- Ability to work in office, regulated laboratory, manufacturing, and data center environments.
- Administer and maintain infrastructure supporting GxP and enterprise business systems.
- Manage VMware vSphere environments, including VMware vCenter, ESXi 8 hosts, virtual machines, templates, snapshots, resource allocation, and lifecycle management.
- Administer Microsoft Azure, Microsoft Entra ID, Microsoft 365, Active Directory, Group Policy, DNS, DHCP, and enterprise identity services.
- Support Okta Identity and Access Management, including directory synchronization, Single Sign-On, Multi-Factor Authentication, lifecycle management, and authentication troubleshooting.
- Administer Druva backup and disaster recovery solutions, including backup monitoring, replication, restore testing, and disaster recovery validation.
- Configure, maintain, and troubleshoot Cisco Nexus switching infrastructure, Cisco Meraki switches, wireless infrastructure, security appliances, and cloud-managed networking.
- Deploy operating system, application, and GxP system patches and other enterprise management tools in accordance with approved change management, validation, and cybersecurity procedures.
- Perform scheduled preventative maintenance on servers, virtualization platforms, storage systems, networking equipment, backup systems, and supporting infrastructure.
- Monitor enterprise infrastructure health, capacity, availability, and performance using monitoring and alerting platforms, and proactively identify and resolve issues.
- Troubleshoot complex infrastructure issues involving virtualization, storage, networking, authentication, cloud services, enterprise applications, and supporting systems.
- Participate in change management activities by implementing infrastructure changes in accordance with GxP, validation, cybersecurity, and quality procedures.
- Create and maintain infrastructure documentation, architecture diagrams, standard operating procedures, work instructions, disaster recovery documentation, and technical standards.
- Participate in scheduled maintenance windows and rotating on-call support for critical infrastructure services.
- Industry certifications such as VMware Certified Professional, Microsoft Azure Administrator Associate, Microsoft Certified: Windows Server Hybrid Administrator Associate, Okta Certified Administrator, Cisco CCNA, Fortinet Certified Associate, CompTIA Network+, CompTIA Security+, or ITIL Foundation are considered a plus.
- Experience within a pharmaceutical, biotechnology, medical device, or other GxP-regulated environment is preferred.
Rocket Pharmaceuticals develops gene therapies for severe and rare inherited diseases. It uses an AAV (Adeno-Associated Virus) platform to deliver corrected genes directly into patients, with the goal of producing a therapeutic protein in targeted cells of the heart, liver, eye, or central nervous system to modify the disease. The therapy work involves engineering AAV constructs so the corrected gene is expressed in diseased cells. The company aims to create first-in-class or best-in-class treatments and generates revenue through partnerships with larger pharma companies, grants, and potential future sales of approved therapies. Core values include Trust, Generosity, Curiosity, and Elevation, guiding a patient-centric approach that puts families first and supports ongoing scientific advancement. Overall goal: provide life-changing gene therapies for patients with few options and expand treatment options for rare genetic disorders.
Company Size
201-500
Company Stage
IPO
Headquarters
Cranbury Township, New Jersey
Founded
2015
Get referred to Rocket Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Rocket closed a $180 million PRV sale in June 2026, funding operations into 2028.
- KRESLADI commercial onboarding starts in Q4 2026, creating Rocket’s first recurring product revenue.
- Rocket restarted RP-A501 dosing in August 2026 after FDA hold removal and safety clearance.
What critics are saying
- Putative securities class actions in New Jersey target Rocket’s Danon disclosures and management credibility.
- Rocket cut roughly 30% of staff and de-prioritized FA and PKD in 2026.
- A Danon setback kills Rocket’s cardiovascular thesis and leaves KRESLADI too small alone.
What makes Rocket Pharmaceuticals unique
- KRESLADI became Rocket’s first FDA-approved gene therapy on March 27, 2026.
- Rocket owns proprietary AAV manufacturing and runs cardiovascular gene therapy programs in-house.
- Rocket targets ultra-rare genetic diseases, where approved competition remains limited and specialized.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Wellness Program
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Rocket Pharmaceuticals shares fell on Friday after the company reported first-quarter 2026 results that missed expectations. The company posted a loss of 42 cents per share, wider than the Zacks Consensus Estimate of 41 cents, and recorded no revenues during the quarter. General and administrative expenses declined 39.8% year over year to $17.1 million, whilst research and development expenses fell 12.2% to $31.5 million, reflecting disciplined spending following organisational restructuring. The company ended the quarter with $144.4 million in cash and investments. In March, the FDA granted accelerated approval to Rocket's gene therapy Kresladi for treating severe leukocyte adhesion deficiency-I. The company also recently agreed to sell its Priority Review Voucher for $180 million to support its cardiovascular pipeline.
Rocket Pharmaceuticals reported first quarter 2026 financial results, highlighting progress across its cardiovascular gene therapy pipeline. The company received FDA accelerated approval for KRESLADI for severe leukocyte adhesion deficiency-I in March 2026 and subsequently sold its Rare Pediatric Disease Priority Review Voucher for $180 million in April. The company has reinitiated dosing in its pivotal Phase 2 study of RP-A501 for Danon disease following a clinical hold lift, with a programme update expected in the second half of 2026. First patient dosing for RP-A701 in BAG3-associated dilated cardiomyopathy is anticipated mid-2026. First quarter net loss was $47.6 million, down from $61.3 million year-over-year. Cash, cash equivalents and investments totalled $144.4 million as of 31 March 2026, which together with PRV proceeds extends the expected cash runway into the second quarter of 2028.
Rocket Pharmaceuticals has raised $180 million through the sale of its Rare Pediatric Disease Priority Review Voucher, extending its cash runway into the second quarter of 2028. The voucher was awarded following the FDA's accelerated approval of KRESLADI, the company's gene therapy for a rare paediatric disease. The proceeds will support Rocket's cardiovascular gene therapy pipeline, which includes three clinical-stage programmes targeting major inherited cardiomyopathy subtypes: Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy. These conditions collectively affect over 100,000 patients in the US and EU. The commercial-stage biotechnology company, which trades on Nasdaq under ticker RCKT, maintains proprietary AAV manufacturing capabilities and multi-year efficacy and safety data in cardiac gene therapy.
Rocket Pharmaceuticals receives FDA approval for KRESLADI gene therapy. Alexandra Moore Published Mar 30, 2026 - 04:18 Smallest Font Largest Font Rocket Pharmaceuticals recently announced a significant regulatory achievement, as the U.S. Food and Drug Administration (FDA) granted approval for KRESLADI. This gene therapy targets a rare pediatric disorder, marking the company's inaugural marketed product and a pivotal regulatory success after an extended review process, as reported by Detik Finance. This approval is particularly notable as KRESLADI becomes the first FDA-sanctioned gene therapy for this specific condition. The development positions Rocket Pharmaceuticals to establish a commercial presence within the ultra-rare disease market. Beyond the product approval itself, Rocket Pharmaceuticals also secured a Rare Pediatric Disease Priority Review Voucher. This asset offers biotech companies a valuable monetization opportunity. Management is actively exploring various strategic options for the voucher to bolster the company's financial flexibility. The company further stated its intentions to make KRESLADI accessible to eligible patients across the United States. Rocket Pharmaceuticals has indicated a controlled, rather than widespread, commercial rollout for KRESLADI. Recent company disclosures describe a tailored commercial strategy designed to address the very limited patient population. Reuters previously reported that the launch is anticipated to commence through a select number of specialized treatment centers. As of December 31, 2025, Rocket Pharmaceuticals held $188.9 million in cash, cash equivalents, and investments. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) operates as a biotechnology firm dedicated to developing genetic therapies for various rare disorders. Its research pipeline encompasses both lentiviral and AAV-based programs, which are aimed at addressing immunological and cardiovascular diseases.
Rocket Pharmaceuticals has received FDA accelerated approval for KRESLADI, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) without an available matched sibling donor for transplant. The approval is based on increased neutrophil CD18 and CD11a surface expression, with continued approval contingent on verification of clinical benefit. LAD-I is an ultra-rare genetic disease affecting approximately one in 100,000 to 200,000 live births in the US, with two-thirds classified as severe. Patients suffer from recurrent, life-threatening bacterial and fungal infections requiring frequent hospitalisation. The FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher, which the company intends to monetise. KRESLADI is now available to eligible patients in the United States through www.KRESLADI.com.